Previous Close | 55.94 |
1-Year Change | 69.88% |
6-Months Change | -16.95% |
3-Months Change | 7.95% |
Moving Avg (50d) | 56.233 |
Moving Avg (200d) | 62.702 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 5.37M |
Beta (3-Years) | 1.11 |
Revenue Growth (ttm) | -94.73% |
Net Profit Margin (ttm) | -6739.96% |
Return On Assets (ttm) | -71.12% |
EPS (ttm) | -5599.57 |
PE Ratio (ttm) | -0.01 |
Dividend Yield | % |
Asset Description: | Cytokinetics, Incorporated |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-16 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
54.821 | 53.143 | 52.024 | 50.346 | 47.549 | 44.752 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.